Business Context and Reporting Period
This Form 8-K, dated March 5, 2024, is filed by AgeX Therapeutics, Inc. (ticker: AGE), a Delaware corporation. The filing reports on a credit drawdown and provides updates regarding a proposed merger with Serina Therapeutics, Inc. (Serina). The registrant is classified as an emerging growth company.
Key Financial Metrics and Obligations
- Debt Obligation: On March 5, 2024, AgeX drew $500,000 under its Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited.
- Repayment Terms: The outstanding principal balance of this note is due and payable on May 9, 2024.
- Revenue and Profit: The filing text does not provide specific revenue, profit, cash flow, or margin figures for the current period.
- Liquidity: Specific cash balance or liquidity metrics are not disclosed in this report, though the filing notes risks regarding the combined company's cash balance post-merger.
Material Changes and Corporate Actions
Merger with Serina Therapeutics
AgeX is proceeding with a previously announced merger agreement (dated August 29, 2023) to acquire Serina Therapeutics, Inc. Upon closing, Serina will become a wholly-owned subsidiary of AgeX.
Warrant Dividend and Reverse Stock Split
The AgeX Board declared a warrant dividend on March 7, 2024, contingent on stockholder approval at a Special Meeting scheduled for March 14, 2024. Key terms include:
- Reverse Stock Split: Anticipated to be effected on March 14, 2024, with trading on a post-split basis commencing March 15, 2024.
- Warrant Dividend: Three Post-Merger Warrants for every five shares of AgeX common stock held as of the record date (March 18, 2024).
- Post-Merger Warrant Terms: Exercise price of $13.20 per warrant; exercisable for one share of common stock and one Incentive Warrant; expires July 31, 2025.
- Incentive Warrant Terms: Exercise price of $18.00 per warrant; exercisable for one share of common stock; expires four years after the Merger closing.
Guidance, Outlook, and Risks
Management anticipates the combined company will trade on the NYSE American under the ticker symbol "SER." The filing includes extensive forward-looking statements regarding the completion of the merger, the timing of the warrant dividend, and the funding of operations through warrant exercises.
Material Risks and Contingencies
- Transaction Approval: The merger and warrant dividend are contingent upon stockholder approval at the Special Meeting.
- Regulatory and Listing: Risks include failure to obtain NYSE American listing approval or necessary regulatory approvals for Serina's product candidates.
- Financial Uncertainty: Risks regarding the ability to secure additional financing, the potential for lower-than-expected cash balances post-merger, and the ability to generate sufficient revenue to operate at a profit.
- Operational Risks: Challenges in integrating operations, retaining key personnel, and the success of Serina's clinical trials and product development programs.
Investor Verification Checklist
- Verify the outcome of the Special Meeting of Stockholders scheduled for March 14, 2024, regarding the approval of the Merger, Reverse Stock Split, and Warrant Dividend.
- Confirm the effective date of the Reverse Stock Split and the commencement of trading under the new ticker symbol "SER."
- Review the definitive Proxy Statement/Prospectus/Information Statement (filed February 14, 2024) for detailed terms of the merger and warrant agreements.
- Monitor the repayment status of the $500,000 Secured Note due on May 9, 2024.
- Assess the combined company's cash runway and financing plans as detailed in the Form S-4/S-1 registration statement.